Tyra Biosciences, Inc. (NASDAQ:TYRA) Short Interest Update

Tyra Biosciences, Inc. (NASDAQ:TYRA) was the recipient of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 3,680,000 shares, an increase of 30.5% from the January 31st total of 2,820,000 shares. Based on an average daily volume of 234,600 shares, the days-to-cover ratio is currently 15.7 days. Approximately 11.9% of the shares of the company are short sold.

Insider Buying and Selling

In related news, Director Nina S. Kjellson sold 3,993 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total value of $65,325.48. Following the completion of the sale, the director now owns 3,707,420 shares in the company, valued at $60,653,391.20. This trade represents a 0.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 21,998 shares of company stock valued at $344,818 over the last three months. 15.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Tyra Biosciences

A number of large investors have recently modified their holdings of the company. RA Capital Management L.P. raised its holdings in Tyra Biosciences by 2.1% in the fourth quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company’s stock valued at $147,858,000 after buying an additional 220,681 shares during the period. Alta Partners Management Company L.P. purchased a new stake in Tyra Biosciences during the 4th quarter worth approximately $56,716,000. FMR LLC raised its holdings in Tyra Biosciences by 0.8% in the third quarter. FMR LLC now owns 3,372,850 shares of the company’s stock valued at $79,296,000 after acquiring an additional 26,187 shares in the last quarter. Boxer Capital Management LLC bought a new position in shares of Tyra Biosciences during the fourth quarter worth about $28,185,000. Finally, Janus Henderson Group PLC lifted its holdings in Tyra Biosciences by 63.6% during the 4th quarter. Janus Henderson Group PLC now owns 1,746,320 shares of the company’s stock worth $24,291,000 after buying an additional 679,124 shares during the last quarter. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Tyra Biosciences Stock Up 1.1 %

Shares of TYRA stock traded up $0.12 on Wednesday, reaching $11.07. 192,909 shares of the stock were exchanged, compared to its average volume of 262,582. The stock has a market cap of $560.02 million, a P/E ratio of -6.83 and a beta of 1.05. The firm has a 50 day moving average of $14.10 and a two-hundred day moving average of $17.70. Tyra Biosciences has a 1-year low of $10.65 and a 1-year high of $29.60.

Analysts Set New Price Targets

Several analysts have recently commented on TYRA shares. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a report on Tuesday, February 18th. UBS Group began coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $30.50.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.